1. Academic Validation
  2. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716

Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716

  • Acta Derm Venereol. 2020 Jul 2;100(14):adv00197. doi: 10.2340/00015555-3505.
Carl D Richards 1 Rohan Gandhi Fernando Botelho Lilian Ho John F Paolini
Affiliations

Affiliation

  • 1 Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, L8S4L8 Hamilton, Canada. E-mail: [email protected].
Abstract

To evaluate cellular response to oncostatin M (OSM) in comparison to interleukin (IL)-31, we analyzed monocyte chemoattractant protein 1 (MCP-1) as a readout for OSM responses with and without IL-4, IL-13, anti-OSM receptor β monoclonal antibody KPL-716, and anti-IL-31 receptor α antibody in human epidermal keratinocytes and human dermal fibroblasts in vitro. In human epidermal keratinocytes, OSM significantly induced STAT3 or STAT1 phosphorylation and synergized with IL-13 or IL-4 in elevating MCP-1. In human dermal fibroblasts, OSM results were similar, and Leukemia Inhibitory Factor or IL-31 minimally activated STAT3 but not MCP-1. OSM significantly stimulated mRNA for type II IL-4 Receptor and type II OSM Receptor. KPL-716, not anti-IL-31Rα, significantly attenuated MCP-1 response to OSM and OSM + IL-4 in human epidermal keratinocytes and human dermal fibroblasts. OSM, not Leukemia Inhibitory Factor or IL-31, synergized with IL-4 and IL-13 in human epidermal keratinocytes and human dermal fibroblasts, suggesting therapeutic potential of KPL-716 in inflammatory dermatologic diseases distinct from IL-31 inhibition.

Keywords

inflammatory skin diseases; interleukins; keratinocytes; signaling; pruritus.

Figures
Products